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Abstract
Background: Rhabdomyosarcoma (RMS) is a highly malignant pediatric cancer that is the most common form of
soft tissue tumors in children. RMS cells have many features of skeletal muscle cells, yet do not differentiate. Thus,
our studies have focused on the defects present in these cells that block myogenesis.
Methods: Protein and RNA analysis identified the loss of MEF2D in RMS cells. MEF2D was expressed in RD and
RH30 cells by transient transfection and selection of stable cell lines, respectively, to demonstrate the rescue of
muscle differentiation observed. A combination of techniques such as proliferation assays, scratch assays and soft
agar assays were used with RH30 cells expressing MEF2D to demonstrate the loss of oncogenic growth in vitro and
xenograft assays were used to confirm the loss of tumor growth in vivo.
Results: Here, we show that one member of the MEF2 family of proteins required for normal myogenesis, MEF2D,
is largely absent in RMS cell lines representing both major subtypes of RMS as well as primary cells derived from an
embryonal RMS model. We show that the down regulation of MEF2D is a major cause for the failure of RMS cells
to differentiate. We find that MyoD and myogenin are bound with their dimerization partner, the E proteins, to
the promoters of muscle specific genes in RMS cells. However, we cannot detect MEF2D binding at any promoter
tested. We find that exogenous MEF2D expression can activate muscle specific luciferase constructs, up regulate
p21 expression and increase muscle specific gene expression including the expression of myosin heavy chain, a
marker for skeletal muscle differentiation. Restoring expression of MEF2D also inhibits proliferation, cell motility and
anchorage independent growth in vitro. We have confirmed the inhibition of tumorigenicity by MEF2D in a tumor
xenograft model, with a complete regression of tumor growth.
Conclusions: Our data indicate that the oncogenic properties of RMS cells can be partially attributed to the loss of
MEF2D expression and that restoration of MEF2D may represent a useful therapeutic strategy to decrease tumorigenicity.
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Background
Rhabdomyosarcoma (RMS) is a highly malignant tumor
that is the most common form of soft tissue tumors in
children. It is thought to arise as a consequence of
myogenic precursors failing to differentiate into normal
muscle [1]. There are two major histological categories
of RMS, the embryonal (ERMS) and alveolar (ARMS)
subtypes. The more common form of the disease is the
ERMS subtype, characterized by loss of heterozygosity
at the 11p15 locus, a region which harbors insulin-like
growth factor 2 (IGF2). ARMS, the more aggressive
form of RMS, is characterized by t(2;13)(q35;q14) or t
(1;13)(q36;q14) translocations in many of the tumors
which result in chimeric transcripts that fuse the 5′ DNA
binding domain of PAX3 or PAX7, respectively, to the
transactivation domain of a forkhead transcription factor,
creating novel PAX3/7-FOXO1 fusion proteins [2,3].
Normal myogenesis is controlled by the concerted
activity of the myogenic regulatory factors (MRF), a
group of four highly related bHLH transcription factors
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composed of Myf5, MyoD, Myf6, and myogenin [4]. Myf5
and MyoD function early in the commitment steps of
myogenesis [5]. Myf6, also known as MRF4, is thought to
act both early in myogenesis and later in both myotube
formation and adult muscle maintenance [6]. Myogenin is
involved in the later stages of differentiation by promoting
efficient myoblast fusion and the differentiation of mature
skeletal muscle fibers [7,8].
The MRFs form avid heterodimers with E-proteins
in vitro, and are thought to function as heterodimers
in vivo [9]. Both the E2A splice variants, E12 and E47, and
HEB appear to function in myogenesis [9,10]. Recent
work has shown that E protein interactions can mediate
differentiation in RD cells, which were derived from an
ERMS tumor [11]. The myocyte enhancer factor 2 (MEF2)
is a regulator of many developmental programs, including
myogenesis [12]. MEF2 is encoded by four vertebrate
genes which encode MEF2A, MEF2B, MEF2C and MEF2D.
The MEF2 family is expressed in distinct but overlapping
temporal and spatial expression patterns in the embryo
and adult [13]. Both MEF2C and MEF2D are implicated
in myogenesis [14,15]. MEF2 factors alone do not possess
myogenic activity, but work in combination with the
MRFs to drive the myogenic differentiation program [16].
MEF2 proteins control differentiation, proliferation,
survival and apoptosis in a wide range of cell types.
The N-terminus of the MEF2 proteins contains a highly
conserved MADS box and an immediately adjacent motif
termed MEF2 domain. Together, these motifs mediate
dimerization, DNA binding and co-factor interactions
[17]. The C-terminus of the MEF2 proteins is highly
divergent among the family members and functions as
the transcriptional activation domain. MEF2 proteins
function as endpoints for multiple signaling pathways
and confer a signal-responsiveness to downstream target
genes. MAP kinase pathways are known to converge
on MEF2 [18,19], resulting in a phosphorylation of the
transcriptional activation domain of MEF2 which augments
its transcriptional activity. Calcium signaling pathways
also modulate MEF2 activity through multiple mechanisms
[20-23]. The activity of MEF2 is tightly controlled by class
II HDACs, which bind to the MADS domain and promote
the formation of multiprotein repressive complexes on
MEF2 dependent genes [24]. Phosphorylation of class
II HDACs is mediated by calcium regulated protein
kinases, which promote the nuclear-cytoplasmic shuttling
of the HDACs and subsequent activation of MEF2C
[24,25]. MEF2D promotes late muscle differentiation
through use of alternative MEF2D isoforms which generates
a muscle specific MEF2Dα2 isoform [26], which binds to
the co-activator ASH2L and is resistant to phosphorylation
by PKA and association with HDACs [27].
Rhabdomyosarcoma tumors express the myogenic regu-
latory factors, but the MRFs are unable to promote differ-
entiation [28-30]. Indeed, MyoD and myogenin are used
as diagnostic markers for RMS as they are expressed in
almost every RMS tumor including both major histo-
logical subtypes, embryonal RMS (ERMS) and alveolar
RMS (ARMS) [31]. Several cell lines have been derived
from RMS tumors and the cell lines exhibit many of
the characteristics of RMS tumors. These lines include
RD (ERMS), RD2 (ERMS), RH28 (ARMS) and RH30
(ARMS) cell lines. The RMS cell lines express Myf5, MyoD
and myogenin, but the proteins appear non-functional
[30]. When MRF responsive reporters are transfected
into RD cells, little activity is detected [28,29]. Ectopic
expression of the MRFs does not rescue the block to
differentiation [30], although expression of myogenic
co-factors such as E proteins, in conjunction with
MyoD, or MEF2C can promote differentiation [11,32].
We have shown here that MEF2D expression is affected
at the level of both RNA and protein in four independent
RMS cell lines representing both common subtypes of
RMS and in primary tumor cells from a mouse model
of ERMS. Transfection of MEF2D reactivates muscle
specific reporter gene constructs and muscle specific
gene expression in both RD (ERMS) and RH30 (ARMS)
cell lines. Expression of exogenous MEF2D promotes
differentiation as assayed by myosin heavy chain staining
in the RH30 ARMS cell line. Consistent with these results,
we find that restoration of MEF2D in RH30 cells reduces
proliferation, motility and anchorage independent growth
in vitro. Moreover, the RH30 cells expressing exogenous
MEF2D cannot produce tumors in a xenograft model,
unlike RH30 cells expressing a vector control.
Results
MEF2D is down regulated in RMS cells
To understand the deregulation of myogenesis in RMS
cells, we first determined the level of myogenin, MyoD
and associated co-factors in RMS cells in comparison
to the normal expression levels present during skeletal
muscle differentiation (Figure 1A). Four independently
derived RMS cell lines were used for this analysis. The
ERMS subtype was represented by RD and RD2 cells
and the ARMS subtype was represented by RH30 and
RH28 cells. Murine C2C12 cells, a commonly used myo-
genic cell line, were used as a comparative cell line for
RMS cells. Myogenin was not detectable in proliferating
myoblasts, but was strongly induced upon differentiation.
MyoD was expressed in proliferating myoblasts and
maintained expression during differentiation. We found
that myogenin was expressed in all assayed RMS cell
lines (Figure 1A). The levels of myogenin in most RMS
lines were higher than the level observed in normal dif-
ferentiating myoblasts. The level of myogenin observed
in RD2 cells was not as robust as was observed in the
other RMS lines, but the level was still similar or
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modestly higher than that observed in normal differentiat-
ing myoblasts. We also assayed for MyoD expression
and found that the expression of MyoD was similar to
the expression of MyoD observed in myoblasts (Figure 1A).
The cell lines of the ARMS subtype, RH30 and RH28,
expressed MyoD at levels comparable or slightly higher
to that observed in normal myoblasts. While expressed
at a lower level than that found in ARMS cells, MyoD
expression was also detected in both cell lines of the
ERMS subtype, RD and RD2.
Next, we assayed the expression profile of the co-factors
required by myogenin in C2C12 and RMS cells. We
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Figure 1 MRFs and E proteins are expressed in RMS cells, but MEF2D is severely down regulated at the protein and RNA level.
A. RMS cell lines express myogenin, MyoD and HEB. Extracts from each indicated cell line were western blotted and probed with antibodies
against myogenin, MyoD, HEB and GAPDH. UD represents undifferentiated (proliferating) cells and D2 represents cells subjected to differentiation
conditions for 2 days. B. MEF2D gene expression levels are down regulated in RMS cells. Gene expression was assayed for MEF2D from cell lines
indicated as in A. C. MEF2D protein expression is down regulated in RMS cells. Protein extracts from cell lines indicated as in A. were used for
western blots and probed with antibodies against MEF2D or GAPDH. D. Muscle specific genes are highly down regulated in RMS cells. mRNA
expression for the indicated genes is shown for the indicated cell lines while proliferating (UD) and after differentiation for two days (D2). The
number above the bars in the graphs represent the fold change between the UD and D2 samples.
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looked for the E proteins by assaying for both the E2A
variants and HEB. The E2A locus encodes the two slice
variants, E12 and E47, which differ by differential use
of a single exon [33]. E12/47 and HEB are known to be
expressed in proliferating and differentiating myoblasts.
We found that the RMS cell lines showed apparently
normal levels of expression of HEB (Figure 1A). RD
and RH30 cell lines were used to confirm expression of
E12/47 and we again observed high levels of the E
proteins (Additional file 1: Figure S1).
We next examined the expression of the MEF2 family
in C2C12 cells and RMS cells and found that while
MEF2A, MEF2B and MEF2C were expressed (Additional
file 1: Figure S2), MEF2D was dramatically down regulated
in RMS cells when compared to the levels found in
C2C12 cells (Figure 1B). The down regulation of MEF2D
was also observed in primary cells derived from a mouse
model of ERMS, JW41 (Figure 1B). The expression of
MEF2D at the protein level was determined from extracts
from proliferating cells and cells that were induced to
differentiate for two days. MEF2D was robustly expressed
in C2C12 cells, but was greatly reduced in all RMS
cell lines tested (Figure 1C). HEK293 cells expressing
exogenous MEF2D were used to confirm specificity
of the antibody. Extracts from HEK293 cells expressing
MEF2D were not recognized by antibodies against MEF2C
and extracts from HEK293 cells expressing MEF2C were
not recognized by antibodies against MEF2D (Additional
file 1: Figure S3).
To confirm that muscle specific genes were down
regulated in RMS cells, we assayed for the expression
of several differentiation specific genes in C2C12 cells
and RMS cell lines. Genes chosen for analysis were
leiomodin2 (LMOD2), troponin I type 2, skeletal, fast
(TNNI2), creatine kinase, muscle (CKM) and actin (ACTA1).
We found that, as anticipated, these genes were robustly
up regulated in response to differentiation in C2C12 cells.
However, expression of these genes was at baseline levels
in RMS cells and expression was not significantly induced
by exposure to differentiation conditions (Figure 1D).
MEF2 is not associated with muscle specific promoters
while MRFs and E proteins are present
To determine if the loss of MEF2D affects promoter oc-
cupancy in RMS cells, chromatin immunoprecipitation
assays were performed. We first assayed for the presence
of MEF2D at muscle specific promoters. While MEF2D
was highly down regulated, it was possible that low levels
of MEF2D present in RMS cells could be associated
with DNA. However, we were unable to detect MEF2D
at the promoter of any gene tested. Shown are data from
the TNNI2 promoter (Figure 2A), but the promoters of
LMOD2, desmin (DES) and CKM were also assayed with
similar results (data not shown). To determine if the MRFs
and associated co-factors were present at promoters in
the absence of MEF2D, we assayed for the presence of
myogenin, MyoD and HEB as we have previously shown
that myogenin, MyoD and HEB bind these promoters
during normal myogenesis [34]. Here, we found that
myogenin (Figure 2B), MyoD (Figure 2C) and HEB
(Figure 2D) were bound to muscle specific promoters
in RD and RH30 cells. As the MRF and E-protein bind-
ing profiles were unaffected by the down regulation of
MEF2D, these data suggest that the lack of MEF2D
proteins in RMS cells does not affect the binding of
the MRFs or associated co-factors to muscle specific
promoters, but is likely significant to the inactivity of
the MRFs in RMS cells.
Exogenous expression of MEF2D activates muscle
specific reporters
To determine if the loss of MEF2D contributed to the
inactivity of muscle specific genes RMS cells, we assayed
for activity using muscle specific luciferase reporters.
We used several muscle specific reporters that show
differentiation specific expression and respond to both
myogenin and MyoD [35,36]. Data from all tested reporters
were similar and data for the Lmod2-luciferase reporter
are shown. We have previously characterized the expression
of these reporters and shown that they are active in dif-
ferentiated C2C12 cells, consistent with the expression
pattern of myogenin, and inactive in non muscle cells
such as NIH3T3 cells [35,36]. The Lmod2 reporter con-
struct was transfected into RD and RH30 cell lines and
assayed for luciferase expression (Figure 3A). In the
ERMS line, RD, the Lmod2 reporter had minimal activ-
ity that was modestly above baseline values. The Lmod2
reporter was completely inactive in the ARMS cell line,
RH30. The modest activity of the reporter in RD cells
is interesting as it suggests that the degree of block to
MRF function correlates with the oncogenic potential
of the tumor type.
We next co-transfected MEF2D with the muscle specific
reporters and assayed for expression. The muscle specific
MEF2Dα2 isoform [26] was chosen for our study. Shown
are the results for the Lmod2 reporter. We found that
transfection of MEF2D promoted expression of the Lmod2
reporter in RD and RH30 cells, with a more robust effect
noted in RH30 cells (Figure 3B). Exogenous MyoD and
myogenin were also tranfected with or without MEF2D
but we found that this did not further stimulate the
activation conferred by MEF2D alone (data not shown).
As MEF2D requires the MRFs to function [16,37], the
data suggest that the endogenous levels of MyoD and
myogenin in RD and RH30 cells are sufficient to stimulate
the activation driven by MEF2D.
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Expression of MEF2D activates muscle specific gene
expression in RMS cells
Our data suggested that the loss of MEF2D might be
responsible for the failure of RMS cells to differentiate,
so we next assayed if exogenous expression of MEF2D
could restore muscle specific gene expression and promote
differentiation in RMS cells. RD and RH30 cells were
transfected with a vector only control and an expression
construct for MEF2D and stable drug resistant clones
were selected. However, stable cell lines overexpressing
MEF2D were not recovered for RD cells despite multiple
experimental attempts. TUNEL analysis revealed a high
level of apoptosis in the transfected cells (data not shown).
Thus, we transiently transfected RD cells with vector
control or MEF2D and examined the effect on muscle
specific genes. We also assayed for the expression of the
cyclin-dependent kinase (Cdk) inhibitor p21CIP1/WAF1
(CDKN1A) which is induced early in myoblast differen-
tiation and functions to block cell cycle progression
[38,39]. Induction of p21 in RMS cells is correlated
with growth arrest and differentiation of RMS cells
[40-42] and is required for ceramide-induced G2 arrest
[43]. We confirmed the expression of exogenous MEF2D
in RD cells at the RNA (Figure 4A) and protein level
(Figure 4B). We found that MEF2D expression led to
an upregulation of muscle specific genes (Figure 4C)
and the differentiation specific gene CDKN1A (p21) at
the level of RNA (Figure 4D) and protein (Figure 4E).
Stable RH30 cell lines overexpressing MEF2D were
recovered and screened to confirm expression at the
level of RNA (Figure 5A) and protein (Figure 5B). RH30
cells transfected with vector only control or MEF2D were
induced to differentiate for 2 days and gene expression
analysis revealed an induction of differentiation specific
gene expression in the presence of MEF2D at each gene
tested (Figure 5C). We also found that expression of
CDKN1A (p21) was robustly stimulated upon differen-
tiation in the presence of MEF2D at the level of RNA
(Figure 5D) and protein (Figure 5E). We also examined
myosin heavy chain (MHC) expression, a hallmark of
differentiated cells. As anticipated, C2C12 cells expressed
low levels of MHC while proliferating, but MHC
expression was strongly induced in differentiated cells
(Figure 5F). In RH30 cells, almost no induction of
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Figure 2 Myogenin, MyoD and HEB associate with the TNNI2 promoter while MEF2D does not. ChIP assays in RD and SJRH30 cells were
performed with antibodies against MEF2D (A), myogenin (B), MyoD (C) and HEB (D). Normal rabbit IgG was used as a negative control. Samples
were analyzed with primers corresponding to the TNNI2 promoter.
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MHC could be detected upon differentiation. However,
RH30 cells tranfected with MEF2D robustly restored
MHC expression upon differentiation (Figure 5F). RH30
cells transfected with MEF2D or vector controls were also
immunostained with myosin heavy chain antibodies
following exposure to differentiation conditions for 2 days.
While myosin heavy chain positive cells could not be
identified in RH30 cells transfected with a vector control,
myosin heavy chain positive cells, including multinu-
cleated myofibers, were readily observed in RH30 cells
expressing MEF2D (Figure 5G). We also assayed for up
regulation of myogenin as a marker of differentiation
and found that myogenin was up regulated in the
presence of MEF2D upon differentiation (Figure 5H).
Thus, these results are highly suggestive that the lack
of MEF2D is implicated in the failure of RMS cells to
differentiate.
MEF2D inhibits the proliferation, migration and
anchorage independent growth of SJRH30 cells in vitro
and inhibits RMS tumor growth in vivo
To evaluate the effect of MEF2D expression on cell pro-
liferation, we measured the growth rate of RH30 cells
with vector control or with MEF2D. We found that the
expression of MEF2D inhibited the proliferation rate of
RH30 cells by approximately 2 fold (Figure 6A). To assay
for cell migration, we used the scratch wound assay.
After 8 hours the wounds were colonized to a much
higher degree by RH30 cells with vector control than
RH30 cells with MEF2D (Figure 6B). This difference was
still obvious at 18 hours after wounding. The degree to
which wound healing was delayed appears to be beyond
what could be attributed to the modest growth defect
observed in the cells. Next, we examined the effects of
MEF2D expression on attachment independent clonal
growth of cells in a soft agar assay, a hallmark of cell
transformation. We found that RH30 cells showed a strong
capacity for colony formation in this assay and that
MEF2D expression almost entirely blocked the ability
of RH30 cells to grow in an anchorage independent
manner (Figure 6C). The modest growth delay in MEF2D
expressing cells cannot account for the lack of clonal
growth observed in this assay as cells were grown for
30 days in soft agar.
Finally, we tested whether MEF2D expression in ARMS
cells could act as an endogenous antitumor factor in vivo.
2 × 106 cells from vector control RH30 cells or RH30
cells expressing MEF2D were injected into the hind
limb of nude mice and the tumor size was measured
every five days. RH30 cells transfected with a vector
control formed visible tumors within the first 2 weeks.
In contrast, overexpression of MEF2D led to a complete
block of tumor growth (Figure 7A and B). Mice were
sacrificed at 4 weeks and tumors resulting from the vector
control RH30 cells were dissected, measured and weighed.
The overall tumor sizes in each case were comparable
(Figure 7C).
Discussion
Here, we have shown that MEF2D is highly down regu-
lated in four independently derived RMS cell lines
representing the two major subtypes of RMS as well as
primary cells derived from an ERMS model of RMS.
Reestablishment of MEF2D expression in both RD cells,
which represent the ERMS subtype and RH30 cells,
which represents the ARMS subtype, activates muscle
specific gene expression and the cell cycle regulator
p21, suggesting that the loss of MEF2D contributes to
the inactivity of myogenin and MyoD in RMS cells and
inhibits differentiation. Our results suggest that the
down regulation of MEF2D is a common feature in
both common subtypes of RMS. Significantly, we have
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cells but can be stimulated by exogenous MEF2D. A. Muscle
specific reporters show minimal activity in RD cells, but are completely
inactive in RH30 cells. Indicated cell lines were transiently transfected
with increasing concentrations of a muscle specific reporter construct.
A luciferase reporter containing the leiomodin (Lmod2) promoter was
used. pGL3 basic was used as the negative control. This value was set
to 1, and all other values presented are relative to this value. pGL3+,
which contains the constitutive CMV promoter, was used as the
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described in A.
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found that restoring MEF2D expression in these cells
impairs the ability of RH30 cells to migrate and grow in
an anchorage independent manner in vitro and form
tumors in vivo. Thus, MEF2D appears to significantly
prevent the oncogenic growth properties of the aggressive
ARMS subtype of RMS.
The regulation of MEF2D is not currently understood,
but the lack of expression in both subtypes of RMS
suggests that a common pathway contributes to the
silencing, such as the inactivity of the MRFs. The MRFs
may promote the expression of MEF2D which is then
required for MRF activity on differentiation specific genes.
MEF2D cooperates with MyoD to recruit RNAPII and
activate transcription at late gene promoters [15]. Myogenin
cooperates with MEF2D to recruit the Brg1 ATP-dependent
chromatin remodeling enzyme to alter chromatin structure
and promote late muscle gene expression [37]. Under-
standing the regulation of MEF2D will be an important
future direction for our studies in efforts to understand
how to reactivate this critical regulator of cell growth
and differentiation in RMS cells.
Alterations in the activity or expression of the MEF2
family have previously been implicated in RMS. Inactivation
of the p38 MAP kinase has been shown to contribute
to RMS and the enforced expression of an activated
MAP kinase restored MyoD function and enhanced
MEF2 activity in a GAL4 tethered reporter assay [44].
In this work, it was suggested that the enhancement of
MEF2 activity by p38 could contribute to the rescue of
myogenic program in RMS cells [44]. It has also been
shown that MEF2 dependent reporters have reduced
activity in RMS cells and that the reduced activity of
GAL4-MEF2 can be induced by expression of the steroid
receptor co-activator SRC-2 [45]. A previous study which
assayed gene expression changes in a murine model of
alveolar rhabdomyosarcoma detected a down regulation
of Mef2c in these tumors [46]. It has also been shown
that expression of MEF2C in RD cells promotes the
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expression of differentiation specific genes [32]. Taken
together, the data suggest that the entire MEF2 family
may be inactivated through multiple mechanisms in
RMS cells and fully understanding the inactivation of
the MEF2 family will be essential in understanding the
pathology of RMS cells.
The activity of MEF2 proteins is influenced by variety
of intracellular signaling pathways and by interaction
with many coactivators and corepressors. Class II his-
tone deacetylases (HDAC), which include HDAC-4, -5,-
7 and −9, are central regulators of MEF2C activity
[24,47-49]. Class II HDACs inhibit MEF2 activity and it
has been shown that MEF2 regulates HDAC9 gene
expression in a negative feed forward regulatory loop
[50]. MEF2D employs alternative isoforms to regulate
differentiation. The ubiquitously expressed MEF2Dα1 is
phosphorylated by PKA and bound by HDACs to function
as a transcriptional repressor, while the muscle specific
MEF2Dα2 isoform is resistant to phosphorylation and
binds to the co-activator ASH2L [27]. An important future
area of study will be the deregulation of HDACs and
potentially the isoform usage of the MEF2 proteins that
may occur in RMS cells and account for the inactivity
of the MEF2 family.
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A surprising aspect of this study was the dramatic
effect of MEF2D on cell motility, migration, anchorage
independent growth and tumor growth in vivo. This
suggests that MEF2D plays an important role in con-
trolling the gene expression of factors that control this
important process. It is surprising that the restoration
of a single transcriptional co-activator could have such
a large effect on the oncogenic properties of these
cells. Our results are highly suggestive that restoring
MEF2D in RMS cells may effectively impede tumor
growth and dissemination.
Our work contributes to the growing body of work
that shows that expression of myogenic co-factors can
rescue the block to differentiation in RMS cells [11,32]
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and indicates that deregulation of required co-factors
for appropriate muscle specific gene expression is a
common mechanism utilized by RMS cells to overcome
terminal differentiation signals.
Conclusions
We have found that MEF2D is silenced in RMS cells
representing both common subtypes of the disease. Our
work suggests that reactivating MEF2D in RMS cells is
an attractive therapeutic target for inhibiting the tumor
growth of these cells which may provide new insight into
treatment of this pediatric cancer.
Methods
Cell culture
RD and SJRH30 (RH30) cells (ATCC) were grown in
Dulbecco’s modified Eagle medium (DMEM) supple-
mented with 10% fetal bovine serum (Hyclone) according
to standard protocols. RD2 and RH28 were obtained from
Denis Guttridge, Ohio State University, and grown as
described above. All cell lines were authenticated by
Bio-Synthesis (Lewisville, TX) using STR analysis on
September 14, 2011. JW41 cells, isolated from an ERMS
tumor from a p53−/−/c-fos−/− mouse [51], were the gift of
Charlotte Peterson, University of Kentucky. Proliferating
C2C12 myoblasts (ATCC) and HEK293 cells (ATCC)
were grown in DMEM supplemented with 10% fetal bo-
vine serum (Hyclone). To induce differentiation of C2C12
myoblasts into myotubes, cells were grown to 70% conflu-
ence and the media switched to DMEM supplemented
with 2% horse serum (Hyclone). C2C12 cells were
grown in differentiation medium for the number of days
indicated in each experiment.
Western blot analysis
Cell extracts were made by lysing PBS washed cell pellets
in radio-immunoprecipitation assay buffer (RIPA) sup-
plemented with protease inhibitors (Complete protease
inhibitor, Roche Diagnostics). Following incubation on ice,
clear lysates were obtained by centrifugation. Protein
concentrations were determined by Bradford’s assay
(Bio-Rad). For each sample, 30 μg of protein was loaded
on each gel. Proteins were transferred onto a PVDF
membrane using a tank blotter (Bio-Rad). The membranes
were then blocked with 5% milk and 1X Tris buffered
saline plus tween 20 (TBST) and incubated with primary
antibody overnight at 4°C. Membranes were then washed
with 1X TBST and incubated with the corresponding
secondary antibody. Membranes were again washed with
1X TBST, incubated with chemiluminescent substrate
according to manufacturer’s protocol (SuperSignal, Pierce)
and visualized by autoradiography. The antibodies used
include anti-MEF2D (P-17, Santa Cruz Biotechnologies),
anti-MEF2C (E-17, Santa Cruz Biotechnologies), anti-HEB
(A-20, Santa Cruz Biotechnologies), anti-myogenin (F5D,
Developmental Studies Hybridoma Bank), anti-MyoD
(5.8A, Santa Cruz Biotechnologies), anti-MHC (MF-20,
Developmental Studies Hybridoma Bank) and anti-
GAPDH (Millipore).
Gene expression analysis
RNA was isolated from cells by Trizol extractions (Invitro-
gen). Following treatment with DNase (Promega), two
micrograms of total RNA was reversed transcribed with
MultiScribe™ MuLV reverse transcriptase (Applied Bio-
systems). cDNA equivalent to 40 ng was used for quan-
titative polymerase chain reaction (qPCR) amplification
(Applied Biosystems) with SYBR green PCR master mix
(Applied Biosystems). Samples in which no reverse
transcriptase was added (no RT) were included for each
RNA sample. The relative levels of expression of genes
were normalized according to those of hypoxanthine
guanine phosphoribosyl transferase (HPRT). qPCR data
were calculated using the comparative Ct method (Applied
Biosystems). Standard deviations from the mean of the
[Δ] Ct values were calculated from three independent
RNA samples. Primers are described in Additional file 1:
Table S1. Where possible, intron spanning primers were
used. All quantitative PCR was performed in triplicate
and three independent RNA samples were assayed for
each time point. qPCR gene expression data are shown
using two formats. For measurements of relative gene
expression (fold stimulation), a fold change was calculated
for each sample pair and then normalized to the fold
change observed at HPRT. For relative measurements
of mRNA expression levels (mRNA expression), gene
expression levels were quantitated using a calibration
curve based on known dilutions of concentrated cDNA.
Each mRNA value was normalized to that of HPRT.
Fold change was calculated by dividing the mRNA
expression values of each sample pair.
Chromatin immunoprecipitation
ChIP assays were performed and quantified as described
previously [34] with the following modifications: 1 × 107
cells were used for each immunoprecipitation and protein
A agarose beads (Invitrogen) were used to immunopre-
cipitate the antibody:antigen complexes. The following
antibodies were used: anti-MEF2D (P-17, Santa Cruz
Biotechnology), anti-MyoD (5.8A, Santa Cruz Biotech-
nology), anti-myogenin (F5D, Developmental Studies
Hybridoma Bank), anti-HEB (A-20, Santa Cruz Biotech-
nology). Rabbit IgG (Santa Cruz Biotechnology) was
used as a non-specific control. Primers are described in
Additional file 1: Table S1. The real time PCR was per-
formed in triplicate. Values of [Δ] [Δ] Ct were calculated
using the following formula based on the comparative Ct
method: Ct, template (antibody) - Ct, template (IgG) = [Δ]
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Ct. Fold enrichments were determined using the formula :
2 - [Δ] Ct. (experimental)/2 -[Δ] Ct (reference, CHR19).
Standard error from the mean was calculated from
replicate [Δ][Δ] Ct values obtained from at least three
individual experiments.
Cell transfections and luciferase assays
RD or RH30 cells were transfected with calcium phosphate
according to standard protocols. The plasmids EMSV-
myogenin (gift of D. Edmondson, U.T. Medical School
at Houston) and pEMCIIs (provided by Andrew Lassar,
Harvard Medical School) were used for expressing
myogenin and MyoD, respectively. The plasmids pcDNA-
MEF2C and pcDNA-MEF2D (gift of Eric N. Olson,
University of Texas Southwestern Medical Center) were
used for expressing MEF2C and MEF2D, respectively.
pcDNA-MEF2D contains the MEF2Dα2 isoform of MEF2D.
Luciferase activity was determined using the Dual-
Luciferase Reporter Assay System (Promega). RH30 or
RD cells were seeded at a density of 5 × 103 cell per
well in 96 well plates and transfected with 0.4 ug of
DNA. Transfections were normalized to Renilla luciferase.
Transfections were performed in triplicate and all data
sets were repeated at least twice.
Stable cell lines
Stable SJRH30 cell lines overexpressing exogenous MEF2D
were made by transfecting SJRH30 cells with linearized
pcDNA-MEF2D plasmid or the empty vector, linearized
pcDNA3.1, and selecting for geneticin (400 ug/ml) resistant
colonies. Individual clones were isolated and propagated.
Immunohistochemistry
Cells were grown on cover slips, fixed with paraformal-
dehyde, incubated with goat serum and 1.0% NP-40 for
one hour and washed with PBS. Primary antibodies against
myosin heavy chain (1:100, MF20, Developmental Studies
Hybridoma Bank) were incubated overnight at 4°C, washed
with PBS and detected by Alexa Fluor-488 goat anti-mouse
antibody (1:500, Invitrogen). Cell nuclei were then stained
by incubating with DAPI (1 μM, Invitrogen) for 5 min.
Proliferation
Cells were seeded in a six well plate at 6 × 104 per well
and harvested every two days for cell counts with a
hemocytometer. All counts were performed in triplicate
and individual experiments repeated three times.
Scratch wound assay
Cells were grown to 100% confluency and the cell mono-
layer was scraped in a straight line to create a “scratch”
with a p200 pipet tip. The debris was removed and the
edge of the scratch smoothed by washing the cells once
with 1 ml of growth medium. Markings were created near
the scratch to obtain the same field during the image
acquisition. The tissue culture dish was then placed in a
tissue culture incubator at 37°C for 0–18 hours.
Soft agar assay
Soft agar assays were carried out in 60 mm dishes in
which 2 ml of 0.7% Noble agar (USB) in 1X DMEM
with 10% FBS was overlaid with 2 ml of 0.35% agar in
1X DMEM with 10% FBS containing the cells. RH30-
pcDNA3.1 (vector) and RH30-MEF2D cells were grown
to 100% confluence, trypsinized, and dispersed. Cells of
each clone (3 × 105) were plated in triplicate. 1 ml of
culture medium was added to the top of each plate
every 5 days and cells were grown at 37°C for 30 days.
The plates were stained with 1 ml of 0.05% Crystal Violet
(Fisher) for > 1 hour and colonies were counted using a
dissecting microscope.
Xenograft
For in vivo tumor formation, cells were harvested by
trypsin treatment and counted. Cells were washed with
PBS and suspended at 106 cells/100 μl in PBS. 2 × 106
cells were subcutaneously injected into the hind flanks
of 10 week old female athymic nude mice (Foxn1nu/
Foxn1nu, Jackson Laboratory). Eight animals were used,
and each animal was injected with RH30-pcDNA3.1
cells in the right flank and RH30-MEF2D cells in the
left flank. Mice were monitored every other day and
tumor dimensions were measured with electronic calipers.
Tumor size was estimated by using the modified ellipsoid
formula 1/2(length × width2). All animal experiments were
conducted according to procedures approved by the Insti-
tutional Animal Care and Use Committee at Southern
Illinois University.
Statistics
qPCR data are presented as means ± standard deviation
(SD). Tumor volume data are also presented as means ±
standard deviation (SD). Tumor weight data are repre-
sented with a box plot, a graphical description of groups
of numerical data through quartiles. Statistical compari-
sons were performed using unpaired two-tailed Student’s
t tests, with a probability value of <0.05 taken to indicate
significance.
Additional file
Additional file 1: Figure S1. E proteins are expressed normally in RMS
cells. Extracts from the indicated cell lines were normalized for total
protein concentration by Bradford assays and used for western blot
analysis. The blots were probed with antibodies against E2A (V-18, SCBT)
and GADPH (6C5, Millipore). Figure S2. MEF2A, MEF2B and MEF2C are
expressed in RMS cells. A. Quantitative gene expression analysis was
performed on cDNA derived from each of the indicated cell lines. Real
time PCR was performed in triplicate on three independent RNA
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isolations. Data is plotted as mRNA expression levels and error bars
indicate standard deviation from the mean. B. Western blot data for
MEF2A, MEF2B and MEF2C. HEK293 cells transfected with individual MEF2
expression constructs were used as positive controls. Antibodies used
included anti-MEF2A (#9736,Cell Signaling), anti-MEF2B (ab33540, Abcam)
and anti-MEF2C (E-17, SCBT). Protein extracts were normalized prior to
loading. Figure S3. Characterization of antibodies against MEF2. A. An
antibody against MEF2C recognizes MEF2C and does not cross react with
MEF2D. HEK cells transiently transfected with plasmids encoding MEF2C,
MEF2D or the empty vector (pcDNA) were harvested for protein and
used for western blot analysis. Blot was probed with anti-MEF2C anti-
bodies (E-17, Santa Cruz Biotechnologies). B. An antibody against MEF2D
recognizes MEF2D and does not cross react with MEF2C. HEK cells transiently
transfected as in A. were used for western blot analysis. Blot was probed with
anti-MEF2D antibody (P-17, Santa Cruz Biotechnologies). Table S1. Primers
used in study.
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